Summarized by Masters of Longevity from Startupticker.ch.
Roundup of Swiss biotech advancements and support initiatives covering clinical progress, imaging diagnostics, novel oncology publications, and new lab space for startups.
Key Takeaways
- Find everything from accelerators to investors and meet like-minded people in thestartup community.
- From positive clinical developments to support offers for biotech startups Stress urinary incontinence (SUI) is a high unmet medical need, affecting more than 150 million women worldwide, for which no approved therapy presently addresses the underlying cause.
- MUVON Therapeutics advancing a muscle precursor cell-based tissue-engineered (MPCCOL) therapy for SUI has recently announced positive interim results from its 12-month Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE-MPC2 ( NCT05534269 ).
